Clinical Trial Update: Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine plus imatinib as first-line therapy for locally advanced or metastatic pancreatic cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-12-27